GKOS 250117 160.00C (GKOS250117C160000) Stock Options, News & Quotes

US OptionsDetailed Quotes

GKOS250117C160000

Watchlist

0.50
0.000.00%

15min DelayTrading Jan 16 15:22 ET

0.00High0.00Low

Intraday

5D
Daily

News

Wells Fargo Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $153
Moomoo NewsJan 16 05:31 ET · Ratings
Wells Fargo Sticks to Their Buy Rating for Glaukos (GKOS)
TipRanksJan 16 05:18 ET · Ratings
Positive Outlook for Glaukos Driven by Encouraging IDose Data and Promising Pipeline Developments
TipRanksJan 15 06:18 ET
Unusual Options Activity: PAA, CFLT and Others Attract Market Bets, PAA V/OI Ratio Reaches 163.9
Moomoo NewsJan 14 16:30 ET
Glaukos Highlights Advances in Glaucoma Treatments
TipRanksJan 14 16:29 ET
Glaukos Says IDose TR Showed Sustained Substantial IOP Reductions in Phase 3
TipRanksJan 14 16:10 ET

Comments

Moomoo AI

Jan 21, 2024 08:51

Glaukos' revenue growth is the market's focus due to its unprofitability. The 88% share price gain is solid, not standout. Market sentiment is lukewarm, hinting at potential stronger growth trends. Recent sentiment is positive due to strong share price momentum.

Investors Bid Glaukos (NYSE:GKOS) up US$137m Despite Increasing Losses YoY, Taking One-year Return to 88%

Meltyy

Dec 19, 2023 01:33

PDUFA Update…

Last week’s PDUFAs:
$Arcutis Biotherapeutics (ARQT.US)$ : Approved 12/15
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co (MRK.US)$ : Approved 12/15
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos (GKOS.US)$ : Approved 12/14
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co (MRK.US)$ : Approved ...

Meltyy

Dec 4, 2023 01:48

PDUFA Events for December 2023

The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics (CRSP.US)$ $Vertex Pharmaceuticals (VRTX.US)$ $OptiNose (OPTN.US)$ $Arcutis Biotherapeutics (ARQT.US)$ $Calliditas Therapeutics (CALT.US)$ $bluebird bio (BLUE.US)$ $Glaukos (GKOS.US)$ $Ionis Pharmaceuticals (IONS.US)$ $Amgen (AMGN.US)$ $Merck & Co (MRK.US)$

Moomoo AI

Nov 3, 2023 06:30

Glaukos' stock carries risk due to losses and high debt, despite cash reserves. The absence of EBIT level profits and free cash flow make sustainability questionable. Investors should proceed with caution.

Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Rockhoundj

Nov 5, 2022 02:23

Let’s see if this bounces

$Glaukos (GKOS.US)$
im seeing some decent chart upside here
thoughts?